These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 22211836)
21. Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study. Pozzi S; Gentile M; Sacchi S; Marcheselli R; Corso A; Cocito F; Musto P; Guarini A; Minoia C; Vincelli I; Ria R; Rivolti E; Mele G; Bari A; Mazzone C; Badiali S; Marcheselli L; Palumbo A; Morabito F Leuk Lymphoma; 2017 Mar; 58(3):552-559. PubMed ID: 27442600 [TBL] [Abstract][Full Text] [Related]
22. Vorinostat in Combination With Lenalidomide and Dexamethasone in Lenalidomide-Refractory Multiple Myeloma. Bilotti E; Vesole DH; McBride L; Schmidt L; Gao Z; Gilani M; McNeill A; Bednarz U; Richter J; Mato A; Graef T; Siegel DS Clin Lymphoma Myeloma Leuk; 2016 Oct; 16(10):558-562. PubMed ID: 27769558 [TBL] [Abstract][Full Text] [Related]
23. Adjusting for patient crossover in clinical trials using external data: a case study of lenalidomide for advanced multiple myeloma. Ishak KJ; Caro JJ; Drayson MT; Dimopoulos M; Weber D; Augustson B; Child JA; Knight R; Iqbal G; Dunn J; Shearer A; Morgan G Value Health; 2011; 14(5):672-8. PubMed ID: 21839405 [TBL] [Abstract][Full Text] [Related]
24. Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment. Dimopoulos MA; Stewart AK; Masszi T; Špička I; Oriol A; Hájek R; Rosiñol L; Siegel D; Mihaylov GG; Goranova-Marinova V; Rajnics P; Suvorov A; Niesvizky R; Jakubowiak A; San-Miguel J; Ludwig H; Ro S; Aggarwal S; Moreau P; Palumbo A Blood Cancer J; 2017 Apr; 7(4):e554. PubMed ID: 28430175 [TBL] [Abstract][Full Text] [Related]
25. Phase I study of once weekly treatment with bortezomib in combination with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma. Totani H; Ri M; Kato C; Nakashima T; Suzuki N; Hagiwara S; Kanamori T; Murakami S; Masuda A; Kinoshita S; Yoshida T; Narita T; Ito A; Kusumoto S; Ishida T; Komatsu H; Iida S Int J Hematol; 2016 Mar; 103(3):316-21. PubMed ID: 26715148 [TBL] [Abstract][Full Text] [Related]
26. Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma. Jimenez-Zepeda VH; Reece DE; Trudel S; Chen C; Tiedemann R; Kukreti V Leuk Lymphoma; 2013 Mar; 54(3):555-60. PubMed ID: 22881043 [TBL] [Abstract][Full Text] [Related]
27. Pomalidomide with or without dexamethasone for relapsed/refractory multiple myeloma in Japan: a retrospective analysis by the Kansai Myeloma Forum. Matsumura-Kimoto Y; Kuroda J; Kaneko H; Kamitsuji Y; Fuchida SI; Nakaya A; Shibayama H; Uoshima N; Yokota I; Uchiyama H; Yagi H; Kosugi S; Matsui T; Ishikawa J; Matsuda M; Ohta K; Iida M; Tanaka H; Kobayashi M; Wada K; Shimazaki C; Nomura S; Imada K; Hino M; Matsumura I; Kanakura Y; Takaori-Kondo A; Int J Hematol; 2018 May; 107(5):541-550. PubMed ID: 29380179 [TBL] [Abstract][Full Text] [Related]
28. Phase II trial of syncopated thalidomide, lenalidomide, and weekly dexamethasone in patients with newly diagnosed multiple myeloma. Tufail M; Siegel DS; McBride L; Bilotti E; Bello E; Anand P; Olivo K; Bendarz U; McNeill A; Vesole DH Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):186-90. PubMed ID: 22381702 [TBL] [Abstract][Full Text] [Related]
29. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide. Richardson P Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100 [TBL] [Abstract][Full Text] [Related]
30. Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. Stadtmauer EA; Weber DM; Niesvizky R; Belch A; Prince MH; San Miguel JF; Facon T; Olesnyckyj M; Yu Z; Zeldis JB; Knight RD; Dimopoulos MA Eur J Haematol; 2009 Jun; 82(6):426-32. PubMed ID: 19302559 [TBL] [Abstract][Full Text] [Related]
31. A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimens. Sanchez L; Vesole DH; Richter JR; Biran N; Bilotti E; McBride L; Anand P; Ivanovski K; Siegel DS Br J Haematol; 2017 Feb; 176(3):440-447. PubMed ID: 27859001 [TBL] [Abstract][Full Text] [Related]
32. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial. Mateos MV; Hernández MT; Giraldo P; de la Rubia J; de Arriba F; Corral LL; Rosiñol L; Paiva B; Palomera L; Bargay J; Oriol A; Prosper F; López J; Arguiñano JM; Quintana N; García JL; Bladé J; Lahuerta JJ; Miguel JS Lancet Oncol; 2016 Aug; 17(8):1127-1136. PubMed ID: 27402145 [TBL] [Abstract][Full Text] [Related]
33. Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma. Scott LJ; Lyseng-Williamson KA Drugs; 2011 Mar; 71(5):625-49. PubMed ID: 21443285 [TBL] [Abstract][Full Text] [Related]
34. The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. Dimopoulos M; Alegre A; Stadtmauer EA; Goldschmidt H; Zonder JA; de Castro CM; Masliak Z; Reece D; Olesnyckyj M; Yu Z; Weber DM Cancer; 2010 Aug; 116(16):3807-14. PubMed ID: 20564094 [TBL] [Abstract][Full Text] [Related]
35. Spotlight on lenalidomide in relapsed or refractory multiple myeloma. Scott LJ; Lyseng-Williamson KA BioDrugs; 2011 Oct; 25(5):333-7. PubMed ID: 21942918 [TBL] [Abstract][Full Text] [Related]
36. Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. San-Miguel JF; Dimopoulos MA; Stadtmauer EA; Rajkumar SV; Siegel D; Bravo ML; Olesnyckyj M; Knight RD; Zeldis JB; Harousseau JL; Weber DM Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):38-43. PubMed ID: 21273172 [TBL] [Abstract][Full Text] [Related]
37. Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study. Trudel S; Tessoulin B; Jullien M; Blin N; Gastinne T; Mahé B; Dubruille V; Bonnet A; Lok A; Chevallier P; Peterlin P; Garnier A; Guillaume T; Le Bourgeois A; Le Gouill S; Moreau P; Touzeau C Ann Hematol; 2019 Jun; 98(6):1441-1447. PubMed ID: 30874851 [TBL] [Abstract][Full Text] [Related]
38. The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy. Tzogani K; Camarero Jiménez J; Garcia I; Sancho-López A; Martin M; Moreau A; Demolis P; Salmonson T; Bergh J; Laane E; Ludwig H; Gisselbrecht C; Pignatti F Oncologist; 2017 Nov; 22(11):1339-1346. PubMed ID: 28935772 [TBL] [Abstract][Full Text] [Related]
39. Low-dose lenalidomide and dexamethasone therapy after melphalan-prednisolone induction in elderly patients with newly diagnosed multiple myeloma. Onishi Y; Yokoyama H; Katsuoka Y; Ito T; Kimura T; Yamamoto J; Nakajima S; Sasaki O; Ara T; Minauchi K; Fukuhara O; Kobayashi N; Noji H; Ota S; Harigae H Ann Hematol; 2020 Oct; 99(10):2351-2356. PubMed ID: 32865607 [TBL] [Abstract][Full Text] [Related]
40. Lenalidomide: an update on evidence from clinical trials. Dimopoulos MA; Terpos E Blood Rev; 2010 Nov; 24 Suppl 1():S21-6. PubMed ID: 21126633 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]